🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the battle against drug-resistant strains of the infection, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are on the rise around the world, with estimates suggesting more than 82 million new cases annually. Particularly high rates are observed in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Receive Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in the same week. This drug, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the drug firm its industry partner to see it through.

“This milestone signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to data released by a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which uses a dual-drug approach. The research involved over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for managing the epidemic. This is considered crucial to lessen the impact of the disease for people and to prevent the spread of untreatable gonorrhoea globally.